Accomplishments

Clinical Practice

CPC Leadership Assists FLASCO Membership

• Held conference call with Florida Blue and UHC to resolve member issues and continue to build working relationship through emails.
• Assisted to resolve 58 clinical practices issues for members regarding Medicare, Medicaid, and private payers reimbursement and coding issues.
• Worked with FL Blue/Availity to provide 2 webinar training hours for members.
• FLASCO assisted Amgen with a letter requesting FCSO to expedite coding revision regarding Neulasta Onpro for the 2017 fee schedule.
• Assisted Biodesix, Inc. to gain a positive coverage decision for the VeriStrat® test
• Assisted nanoString to gain a positive coverage decision for Prosigna.
• Signed a letter of support for Foundation Medicine to further discussion between
• BCBS of Florida to determine appropriate coverage levels for genomic profiling tools.
• Assisted Takeda Oncology with Ninlaro indication discrepancy
• Monitored USP 797 and 800 Revision Efforts.
• Strong representation in CAC
• FLASCO participated in Medicaid Formulary Meeting. Encouraged members to apply for a seat on committee.

CPC Leadership Assists Corporate Members

• Developed a process with enhanced criteria to be met before Clinical Practice will sign onto letter of support
• At the invitation of the Clinical Practice Chairman several Diamond Corporate Members met face to face with chairman to discuss challenges and build stronger working relationships to learn how to provide better education to FLASCO members.

Communications

• FLASCO Branding Presence
• Created New To Oncology Physician Assistants and Nurse Practitioner forum
• Developed the FLASCO phone App for both Android and IPhone securing 132 users.
• Increased FLASCO visibility through social media (Facebook and Twitter)
• FLASCO Newsletters: Flash (weekly), CPC and Administrator (monthly)
• Provided current oncology news through the FLASCO FLASH weekly newsletter.
• Developed and distributed 7 monthly newsletter for Administrator Network andClinical Practice News.
• Membership Representation
• FLASCO represented at ASCO, ACCC, ASH, COA, and NCCN Annual Meetings
• The FLASCO President served as a member on the ASCO Payment Reform Work Group and served on the COA Board of Directors as well as the COA Payment Reform Task Force.
• Outreach to other organizations: FMA, FHCC, CFMSE, LLS, CCRAB, FCONN, and Alliance for Patient Access.
• Strengthened membership and relationship with the academic centers in Florida.
• Developed stronger relationship with Pharmacists in member practices, cancer centers and academic centers to help grow and establish a strong Pharmacists presence within the FLASCO membership.
• Continued to maintain and increase relationship with Puerto Rico physicians.

Legislative

• Actively supported efforts that lead to Congress passing a Bill that would eliminate the Sustainable Growth Rate (SGR) formula.
• Advocated along with other National Healthcare organizations on the Federal level in support of Oral Chemotherapy Parity and Prescription Drug Specialty Tiers.
• Provided a letter of support to ASH in support of a congressional resolution on Sickle Cell Trait.
• Actively supported ASCO, ASH, ACS, FMA and COA on common ground issues.
• Actively advocated other Health Care Issues
• Supported the reconsideration of reimbursement issues regarding 2015 Fee Schedule
• Supported Patient Access Florida HB1001
• Supported Cancer Patient Protection Act HR1416
• Supported 21st Century Cares Act
• Enhanced alliances with the Governmental Affairs Staff of many FLASCO Corporate Members.

Membership

• Increased membership from 1,847 to 2,300 members
• Holy Cross Hospital, Sylvester Comprehensive Cancer Center, and Suncoast Cancer Institute became 100% Member Partners
• The FLASCO Board of Directors agreed to extend Associate level of FLASCO membership to include medical/pharmacy students with an interest in oncology
• The FLASCO Immediate Past President and Executive Director visited Baptist Hospital and University of Miami practices thanking the current members, and encouraging others to join the new FLASCO Membership Campaign.
• 48 corporate members supported FLASCO initiatives.

Program

• Developed and Implemented 7 educational programs for the FLASCO membership or patients and caregivers.
• Co-sponsored or partnered on 21 regional, national, or international programs
• Offered 2 Travel Award to APPs to attend a Best of ASCO® meeting in Florida
• Supported 12 educational activities through our national cancer organizations: ASH,ACCC, COA and ASCO

Fellows Initiative

• Continued presentations on Business Aspects of Oncology to Fellows
• FLASCO supports the leaders of tomorrow by offering financial assistance to attend national meetings
  • 4 Travel Awards to the ASCO Annual Meeting
  • 3 Travel Awards to the ASH Annual Meeting
  • 1 Travel Award to the ASTRO Annual Meeting
  • 1 Travel Award to the SGO Annual Meeting
  • 1 Travel Award to the SSO Annual Meeting
• Poster presentations encouraged to display during FLASCO Fall and Spring Sessions

Patient Advocacy Initiative

• Educated 115 Patients and Caregivers through the “Living with CLL” Patient Advocacy Event funded by Pharmacyclics
• Educated 60 Patients and Caregivers through the “Living with Prostate Cancer” Patient Advocacy Event funded by Bayer Healthcare
• Educated 40 Lung Cancer Patients and Caregivers at a Ft. Lauderdale Patient Advocacy Event funded by Celgene
• Partnered with Pfizer to have Governor Rick Scott of Florida declare February Metastatic Breast Cancer Awareness Month

Clinical Practice

• Continued a strong working relationship with First Coast Service Options (Florida Medicare Contractor), Aetna, Florida Blue, Humana and UHC.
• Assisted and helped resolve a record number of members’ reimbursement issues
• Assisted Biodesix, Inc. to gain a positive coverage decision for the VeriStrat® test from United Healthcare and Aetna.
• Clinical Practice Committee Chair and Co-Chair met face to face two times with Diamond Corporate Members.
• Actively supported further discussion between BCBS of Florida and Foundation Medicine, Inc., to determine appropriate coverage levels for genomic profiling tools.
• Endorsed PAM50, Prosigna test approved by FL Medicare.
• EMEND – Oral vs. IV Aprepitant for Chemotherapy was addressed several times with First Coast Service Options.
• FLASCO requested and FCSO is looking at how they have their system files set up in regards to what provider specialties they believe would have the appropriate training as an Authorized User (AU) of Xofigo.
• Monitored USP 800 Revision Efforts.
• Conducted a FLASCO member survey on biomarkers testing practices in advance NSCLC.
• Surveyed FLASCO members regarding the number of and development of clinical pathways (Celgene).
• Submitted a letter to CMS making recommendations regarding the 2016 Physician Fee Schedule which included the following topics:
• Section 410.26(b)(5) Incident to Proposals: Billing Physician as the Supervising Physician and Ancillary Personnel Requirements.
• Section 1847A: Payment for Biosimilar Biological Products
• CTP Codes for FISH Testing: CPT Codes 88367,88368, 88374, and 88377
• CTP Codes for Flow Cytometry: Codes 88184 and 88185

Communications

• Provided current oncology news through the FLASCO FLASH weekly newsletter.
• Thomas Marsland, MD and the FLASCO Executive Director served as two of the seven members on the ASCO State Affiliate Council Executive Committee.
• FLASCO represented at ASCO, ACCC, ASH, COA, and NCCN Annual Meetings
• The FLASCO President served as a member on the ASCO Payment Reform Work Group and served on the COA Board of Directors as well as the COA Payment Reform Task Force.
• Outreach to other organizations: FMA, FHCC, CFMSE, LLS, CCRAB, FCONN, and Alliance for Patient Access.
• Strengthened membership and relationship with the academic centers in Florida.
• Developed stronger relationship with Pharmacists in member practices, cancer centers and academic centers to help grow and establish a strong Pharmacists presence within the FLASCO membership.

Legislative

• Actively supported efforts that lead to Congress passing a Bill that would eliminate the Sustainable Growth Rate (SGR) formula.
• Advocated along with other National Healthcare organizations on the Federal level in support of Oral Chemotherapy Parity and Prescription Drug Specialty Tiers.
• Provided a letter of support to ASH in support of a congressional resolution on Sickle Cell Trait.
• Actively supported ASCO, ASH, ACS, FMA and COA on common ground issues.
• Actively advocated other Health Care Issues
• Supported the reconsideration of reimbursement issues regarding 2015 Fee Schedule
• Supported Patient Access Florida HB1001
• Supported Cancer Patient Protection Act HR1416
• Supported 21st Century Cares Act
• Enhanced alliances with the Governmental Affairs Staff of many FLASCO Corporate Members.

Membership

• FLASCO increased its membership from 1,476 to 1,847 members
• University of Florida Cancer Center—Orlando Health became a 100% Member in 2015
• The FLASCO Board of Directors agreed to include oncology focused PharmD as FLASCO Regular members. Opened areas of representation from the oncology GYN, Radiation, Pathology, Surgical, Physician Assistant, Nurse, Nurse Navigator and Continuing Education during the bi-annual FLASCO Board meetings.
• The FLASCO Immediate Past President and Executive Director visited several practices thanking the current members, and encouraging others to join the new FLASCO Membership Campaign.
• Each Diamond Member was provided the opportunity to hold two meetings with FLASCO President and one meeting with Clinical Practice Committee Chairman and one meeting with the Clinical Practice Committee Vice-Chairman.

Program

• Developed and Implemented the seventh Annual PA/ARNP/RN Physician Team Statewide Conference, fifth Annual FLASCO Puerto Rico Business of Oncology Conference, sixth Annual FLASCO Business of Oncology Summit, 2015 Spring multi disciplined scientific program and Fall Session with four educational track programs including Multidisciplinary, Pharmacy, Nursing, and Patient Navigator sessions.
• Co-sponsored the 12th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies with Moffitt Cancer Center, Highlights of ASH , Memorial Best of ASCO® Florida Hospital Best of ASCO®
• FLASCO participated in the following local and regional meetings: 12th Annual Miami Cancer Meeting, FHCC Annual Meeting, Value In Healthcare, Mayo Hematology/Oncology Conference and the 9th Annual New Orleans Summer Cancer Meeting
• Cooperated and supported educational activities through our national cancer organizations: ASH, ACCC, COA and ASCO
• Provided 1 Travel Award to Physician’s Assistant to attend a Best of ASCO® meeting in Florida.

Fellows Initiative

• Continued presentations on Business Aspects of Oncology to Fellows
• Provided 4 Fellow Travel Awards to the ASCO Annual Meeting
• Provided 3 Fellow Travel Awards to the ASH Annual Meeting
• Provided 1 Fellow Travel Award to the ASTRO Annual Meeting
• Provided 2 Fellow Travel Award to the SGO Annual Meeting
• Fellow poster presentations at FLASCO Fall Session

Patient Advocacy Initiative

• Educated 45 Multiple Myeloma Patients and Caregivers at a Tampa Patient Advocacy Event funded by Takeda Oncology
• Educated 40 Multiple Myeloma Patients and Caregivers at a Jacksonville Patient Advocacy Event funded by Takeda Oncology
• Educated 40 Lung Cancer Patients and Caregivers at a Ft. Lauderdale Patient Advocacy Event funded by Celgene

FLASCO Foundation

• The FLASCO Board approved supporting the Strategic Plan developed and approved by the FLASCO Foundation Board to re-launch FLASCO Foundation, Inc.

FLASCO Website

• Employed Full time Webmaster
• Redesigned FLASCO website
• Created member dashboard
• Created Hematology Tumor Board forum

Clinical Practice

• Continued a strong working relationship with First Coast Service Options (Florida Medicare Contractor), Aetna, Florida Blue, Humana and UHC
• Assisted and helped resolve a record number of members’ issues regarding Medicare, Medicaid, and private payers billing and coding issues
• FLASCO provided a liaison from the Clinical Practice Committee to all of the Diamond Corporate FLASCO Members
• FLASCO Clinical Practice Committee Chair met face to face two times with Diamond Corporate Members
• FLASCO Select Clinical Practice Committee Members met face-to-face with the Florida Medicare Medical Director and staff to strengthen relationship and work through current Clinical Practice issues

Communications

• Provided current oncology news through the FLASCO Blast weekly newsletter
• The FLASCO Executive Director served as one of the seven members on the ASCO State Affiliate Council Executive Committee. Through this membership networking and idea sharing is created with other oncology state societies.
• Executive Director attended the ASCO February State Affiliate Council Meeting, Board Liaison joined to attend the July CAC Meeting, and the Executive Director attended while the Vice President represented FLASCO on a panel during the October ASCO State Leadership Conference
• The FLASCO Vice President served as a member on the ASCO Payment Reform Work Group and served on the COA Board of Directors as well as the COA Payment Reform Task Force
• Outreach to other organizations: FMA, FHCC, CFMSE, LLS, CCRAB, FCONN, and Alliance for Patient Access
• Strengthening membership and relationship with the academic centers in Florida: University of Florida, University of South Florida, Mayo Clinic Jacksonville and University of Miami
• Continued to maintain and increase relationship with physicians through the Puerto Rico Medical Oncology State Society

Legislative

• Successfully disseminated template letters on specific issues to the FLASCO member practices
• Actively supported ASCO, ASH, ACS, FMA and COA on common ground issues
• Actively advocated Health Care Reform Issues
• Supported the reconsideration of reimbursement issues regarding 2015 Fee Schedule
• Supported Patient Access HB1001
• Supported appeal against Scope of Practice Expansion
• Supported Cancer Patient Protection Act HR1416
• Supported appeal to enact the SGR Repeal and Medicare Provider Payment Modernization Act HR4015
• Enhanced our alliances with the Governmental Affairs Staff of many FLASCO Corporate Members

Membership

• FLASCO increased its membership from 800 to 1,476 members
• FLASCO 2014 Membership Initiative: In an effort to increase engagement among physicians, clinicians and administration (including attendance at events), the FLASCO Board of Directors agreed to extend complimentary membership for physicians, nurse practitioners, physician assistants and office staff from practices, academic centers, and hospitals in the oncology community through December 31, 2016.
• The following practices became 100% Members in 2014: Cancer Care Centers of Brevard, Cleveland Clinic Florida, Florida Hospital Gynecologic Oncology, Florida Oncology Network Enterprises, Hematology and Oncology Consultants, PA, Mayo Clinic Jacksonville, Moffitt Cancer Center, Oncology & Hematology Associates of West Broward, Oncology Resource Networks, Premier Hematology & Oncology, Space Coast Cancer Center and Mid-Florida Hematology and Oncology
• The FLASCO Board of Directors agreed to include oncology focused PharmD as FLASCO Regular members. Opened areas of representation from the oncology GYN, Radiation, Pathology, Surgical, Physician Assistant, Nurse, Nurse Navigator and Continuing Education during the bi-annual FLASCO Board meetings.
• Outreach with FLASCO leadership and Diamond Member: The FLASCO President and Executive Director visited several practices encouraging them to join the new FLASCO Membership Campaign including Florida Hospital Cancer Institute, Premier Hematology & Oncology, Mid Florida Hematology & Oncology Centers, and Florida Cancer Specialists

Program

• Developed and Implemented the sixth Annual PA/ARNP/RN Physician Team Statewide Conference, fourth Annual FLASCO Puerto Rico Business of Oncology Conference, Fifth Annual FLASCO Business of Oncology Summit, 2014 Spring multi disciplined scientific program and Fall Session with four educational track programs including Hematology/Medical Oncology, Radiation, Nursing, and Patient Navigator sessions
• Co-sponsored the 10th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies with Moffitt Cancer Center, Highlights of ASH and the Memorial Best of ASCO®
• FLASCO participated in the following local and regional meetings: Florida Hospital Best of ASCO®, 11th Annual Miami Cancer Meeting, FHCC Annual Meeting, Space Coast Cancer Innovation Improving Value In Healthcare, Mayo Hematology/Oncology Conference and the 8th Annual New Orleans Summer Cancer Meeting
• Cooperated and supported educational activities through our national cancer organizations: ASH, ACCC, COA and ASCO

Fellows Initiative

• Continued presentations on Business Aspects of Oncology to Fellows
• Provided 3 Fellow Travel Awards to the ASCO Annual Meeting
• Provided 3 Fellow Travel Awards to the ASH Annual Meeting
• Provided 1 Fellow Travel Award to the ASTRO Annual Meeting
• Provided 1 Fellow Travel Award to the SGO Annual Meeting

FLASCO Foundation

• The FLASCO Board approved support through FLASCO of a contracted grant writer
• The FLASCO Foundation received first grant to provide an educational program to multiple mylenoma patients and their caregivers in Tampa

Clinical Practice

• Continued a strong working relationship with First Coast Service Options, FL Medicare and private payers, Aetna, BCBS, Humana and UHC.
• Assisted and helped resolve a record number of members’ issues regarding Medicare, Medicaid, and private payers billing and coding issues.
• FLASCO provided a liaison from the Clinical Practice Committee to all of the major Corporate FLASCO Members/Supporters.
• Met face-to-face with FL Medicare Medical Director and staff to strengthen relationship and work through current Clinical Practice issues.

Communications

• Continued Weekly FLASCO Blast to members, Corporate Members, and Payers.
• Executive Director and FLASCO member served as two of the seven members on the ASCO State Affiliate Council.
• Continued to maintain and increase relationship with physicians in Puerto Rico.
• Outreach to other organizations FSGO, FMA, Rheumatology, Pediatric Oncologists, LLS, etc.
• Strengthening membership and relationship with the academic centers in Florida.

Legislative

• Successfully enhanced our alliances with ACS, FMA, COA and the Governmental Affairs Staff of many FLASCO Corporate Members/Supporters.
• Successfully disseminated template letters on specific issues to the FLASCO member practices.
• Actively advocated Health Care Reform Issues.
• Actively supported ASCO, ASH and COA on common ground issues.
• Educated State Legislators on the Mission of FLASCO and encouraged them to utilize FLASCO as a resource – Welcome letters sent to all Florida Legislators.
• FLASCO served as a Coalition Member on the Oral Parity Legislative Issue and actively supported this issue which passed during the 2013 legislative session.
• FLASCO served as a Coalition Member on the Specialty Tiering Issue.

Membership

• FLASCO increased its membership from 350 to 800 members.
• FLASCO new 2014 Membership Initiative—complimentary membership to all physicians, nurses, PAs, and appropriate office staff. Florida Cancer Specialists was the first practice to participate in this initiative. Others participating included, Broward Health, Memorial Cancer Center, University of Florida, Lynn Cancer Institute, and Cassidy Cancer Center.
• Outreach to other specialties, including Radiation Oncology, Gynecologic Oncology, and Surgical Oncology, to increase FLASCO Membership participation by members of these disciplinarians.
• Continued Board and Executive Committee Representation of PAs, NPs, Liaison from Puerto Rico as well as a fellow liaison from each academic centers.
• Outreach with FLASCO leadership and Diamond Member: visited several practices encouraging them to join the new FLASCO Membership Campaign including Broward Health, University of Miami Deerfield, Memorial Cancer Center, and Lynn Cancer Institute.
• FLASCO Legislative Co-Vice Chairman also serves as a member of ASCO on the member of the Payment Reform Work Group and served on the COA Board of Directors and COA Payment Reform Task Force.

Program

• Developed and Implemented the fifth Annual PA/NP Statewide Conference, third Annual FLASCO Puerto Rico Business of Oncology Conference , Fourth Annual FLASCO Business of Oncology Summit 2013 Spring and Fall Sessions with educational programs combining scientific and practical aspects of Oncology practice.
• FLASCO participated in both Mayo Hematology/Oncology Conference and the 8th Annual New Orleans Summer Cancer Meeting.
• Co-sponsored both the 9th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies with Moffitt Cancer Center and the Highlights of ASH
• FLASCO Officer, CPC Representative and Executive Director attended the ASCO January CPC Meeting and the ACCC Presidential Retreat, the July CAC Meeting, and the October ASCO State Leadership Conference.
• Initiated and implemented the first Patient Advocacy Meeting to initiate collaboration between local and regional specialty societies.
• Cooperated and supported educational activities through our state cancer centers, ASH, ASCO, ect.
• FLASCO coordinated training of 28 mid-level providers in palliative care during the Advanced Care Training at the Mayo Simulation Center.

Fellows Initiative

• Continued presentations on Business Aspects of Oncology to Fellows.
• Provided 3 Fellow Travel Awards to the ASCO Annual Meeting.
• Provided 2 Fellow Travel Awards to the ASH Annual Meeting.
• Provided 1 Fellow Travel Award to the ASTRO Annual Meeting.

Administrative

• FLASCO employed an outside accounting firm to perform an audit.
• FLASCO members worked together with a marketing company to formulate a strategy to move forward with an updated face and plan.
• Formed the FLASCO Foundation to continue supporting fellows and residents within the oncology community.
• FLASCO Members and the Executive Director attended and participated in the ASH, ASCO, COA, ACCC, and NCCN Annual Meetings.
• FLASCO Executive Director participated in meetings of the First Coast Service Options Executive Specialty Circle Council.
• The FLASCO Executive Director attended the first-ever FMA Insurance Summit. One of the major outcomes of the meeting revolved around payer contracts.
• Improved the financial status and stability of FLASCO.
• Expanded number of exhibitors and supporters for FLASCO meetings

Clinical Practice

• Continued a strong working relationship with FCSO.
• Continued the Ad Hoc Committee to work with Private Payers (Aetna, BCBS, Humana and UHC)
• Assisted and helped resolve a record number of members’ issues regarding Medicare/private payers billing and coding issues
• FLASCO provided a liaison from the Clinical Practice Committee to all of the major Corporate FLASCO Members/Supporters
• Provided 3 Fellow Travel Awards to the ASCO Annual Meeting
• Provided 3 Fellow Travel Awards to the ASH Annual Meeting

Communications

• Continued Weekly FLASCO Blast to members, Corporate Members, and Payers
• Continued to maintain and increase relationship with physicians in Puerto Rico.
• Outreach to other organizations FSGO, FMA, Rheumatology, Pediatric Oncologists, etc.
• Strengthening membership and relationship with the academic centers in Florida
• Members of the Executive Committee meet with Diamond Corporate Members 2 times during the year
• Continued collaboration between FLASCO and the Florida Health Care Coalition
• Developed the FLASCO/FLHCC Central Florida Oncology Council

Legislative

• Successfully enhanced our alliances with ACS, FMA, COA and the Governmental Affairs Staff of many FLASCO Corporate Members/Supporters
• Successfully disseminated template letters on specific issues to the FLASCO member practices
• Actively advocated Health Care Reform Issues
• Actively supported ASCO, ASH and COA on common ground issues
• Educated State Legislators on the Mission of FLASCO and encouraged them to utilize FLASCO as a resource – Welcome letters sent to all Florida Legislators
• FLASCO Past Legislative Chairman served as a member of ASCO Legislative Committee
• FLASCO took the lead with COA and participated in Capitol Hill Day in September
• FLASCO served as a Coalition Member on the Oral Parity Legislative Issue and actively supported this issue
• FLASCO served as a Coalition Member on the Specialty Tiering Issue

Membership

• FLASCO approved 35 new Regular members, 11 new Affiliate Members, 18 new Associate Member, and 4 new Courtesy Members
• Outreach to other specialties, including Radiation Oncology, Gynecologic Oncology, and Surgical Oncology, to increase FLASCO Membership participation by members of these disciplinarians.
• Continued Board and Executive Committee Representation of PAs, NPs and Liaison from Puerto Rico.
• Conducted an extensive mail and email campaign to all ASCO members with discounted memberships that was successful. 24 new FLASCO members came from this campaign.

Program

• Developed and Implemented the 2012 Spring and Fall Sessions with educational programs combining scientific and practical aspects of Oncology practice
• Developed and implemented the fourth Annual PA/NP Statewide Conference
• Developed and implemented the second Annual FLASCO Puerto Rico Business of Oncology Conference
• Developed and implemented the Third Annual FLASCO Business of Oncology Summit
• Supported the 2012 Highlights of ASH held in Orlando in January 2012
• FLASCO provided Past ASH President and several FLASCO Members for Fellows Presentation at Mayo Hematology/Oncology Conference
• Co-sponsored the following meeting: 7thst Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies” (USF Health, Moffitt Cancer Center and The Univ. of Texas MD Anderson Cancer Center)

FLASCO Officer, CPC Representative and Executive Director attended the ASCO January CPC Meeting and the ACCC Presidential Retreat, the July CAC Meeting, the October ASCO State Leadership Conference and CPC Meeting

• Cooperated and supported educational activities through our state cancer centers, ASH, ASCO and others
• Continued presentations on Business Aspects of Oncology to Fellows at

Research

• FCTN Signed Cooperation Agreement with Cancer Research Network, Inc
• Eight (8) new studies screened by FCTN in 2012. Two of these studies were chosen and will open in early 2013.
• FCTN re-certified two sites
• Successfully completed the ASCO grant to FLASCO for the training of mid-level providers in palliative care and presented the research in a national meeting. Research manuscript accepted for publication in 2013
• FLASCO in collaboration with Sanofi completed a data collection prostate and colorectal project.

Administrative

• FLASCO employed a Marketing and Communication Company to conduct an in-depth survey of membership
• FLASCO formed the FLASCO Foundation, Inc. to assist in providing funds for Fellows Educational activities, and our Patient Advocacy Initiative.
• FLASCO Members and the Executive Director attended and participated in the 2012 ASH Annual Meeting and the ASCO Annual Meeting.
• FLASCO Executive Director attended and exhibited at the OMF Spring Meeting
• FLASCO Executive Director participated in meetings of the FMA Executive Specialty Circle Council
• Improved the financial status and stability of FLASCO
• ASCO President attended and presented at our 2012 Annual Meeting
• Expanded number of exhibitors and supporters for FLASCO meetings
• FLASCO Executive Director attended the COA Annual Meeting
• FLASO Executive Director attended the ACCC Annual Meeting